International Journal of Radiation Oncology * Biology * Physics
Volume 80, Issue 4 , Pages 1080-1086 , 15 July 2011

External Beam Radiotherapy for Prostate Cancer: Urinary Outcomes for Men With High International Prostate Symptom Scores (IPSS)

Presented at the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Los Angeles, CA, Oct 28–Nov 1, 2007.

  • Renuka Malik, M.D.

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL
    • ,
  • Ashesh B. Jani, M.D.

      Affiliations

    • Department of Radiation Oncology, Emory University, Atlanta, GA
    • ,
  • Stanley L. Liauw, M.D.

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL
    • Corresponding Author InformationReprint requests to: Stanley L. Liauw, M.D., Department of Radiation and Cellular Oncology, University of Chicago Hospitals, 5758 S. Maryland Ave., MC 9006, Chicago, IL 60637. Tel: (773) 702-6870; Fax: (773) 834-7340

Received 16 October 2009 ,Revised 8 March 2010 ,Accepted 31 March 2010.

References 

  1. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549–1557discussion 1564
  2. Bucci J, Morris WJ, Keyes M, et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2002;53:91–98
  3. Mabjeesh NJ, Chen J, Stenger A, et al. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy. Urology. 2007;70:548–553
  4. Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 1998;160:1379–1382
  5. Keyes M, Miller S, Moravan V, et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: Long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys. 2009;73:1023–1032
  6. Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;56:1085–1092
  7. Ohashi T, Yorozu A, Toya K, et al. Serial changes of international prostate symptom score following I-125 prostate brachytherapy. Int J Clin Oncol. 2006;11:320–325
  8. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789–799
  9. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: How localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol. 2009;27:3916–3922
  10. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261
  11. Slova D, Lepor H. The short-term and long-term effects of radical prostatectomy on lower urinary tract symptoms. J Urol. 2007;178:2397–2400discussion 2400–2391
  12. Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007;109:2239–2247
  13. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000;92:1582–1592
  14. Shrader-Bogen CL, Kjellberg JL, McPherson CP, et al. Quality of life and treatment outcomes: Prostate carcinoma patients' perspectives after prostatectomy or radiation therapy. Cancer. 1997;79:1977–1986
  15. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003;21:3979–3986
  16. Mohler J, Babaian RJ, Bahnson RR, et al. Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007;5:650–683
  17. Liauw SL, Weichselbaum RR, Rash C, et al. Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer. Technol Cancer Res Treat. 2009;8:201–206
  18. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–181
  19. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  20. Herold DM, Hanlon AL, Hanks GE. Diabetes mellitus: A predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys. 1999;43:475–479
  21. Schultheiss TE, Lee WR, Hunt MA, et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:3–11
  22. Harsolia A, Vargas C, Yan D, et al. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: Dose-volume analysis of a phase II dose-escalation study. Int J Radiat Oncol Biol Phys. 2007;69:1100–1109
  23. Liu M, Pickles T, Berthelet E, et al. Urinary incontinence in prostate cancer patients treated with external beam radiotherapy. Radiother Oncol. 2005;74:197–201
  24. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–1034
  25. Cheung MR, Tucker SL, Dong L, et al. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:1059–1065
  26. Valicenti RK, Winter K, Cox JD, et al. RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?. Int J Radiat Oncol Biol Phys. 2003;57:614–620
  27. Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 1999;85:2460–2468
  28. Feigenberg SJ, Hanlon AL, Horwitz EM, et al. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2005;62:397–405
  29. Borghede G, Hedelin H. Radiotherapy of localised prostate cancer. Analysis of late treatment complications. A prospective study. Radiother Oncol. 1997;43:139–146
  30. Karlsdottir A, Johannessen DC, Muren LP, et al. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol. 2004;71:43–53
  31. Langenhuijsen JF, van Lin EN, Hoffmann AL, et al. Neoadjuvant androgen deprivation for prostate volume reduction: The optimal duration in prostate cancer radiotherapy. Urol Oncol. 2009;In press
  32. Lilleby W, Fossa SD, Knutsen BH, et al. Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation. Radiother Oncol. 2000;57:195–200
  33. Zechmann CM, Aftab K, Didinger B, et al. Changes of prostate gland volume with and without androgen deprivation after intensity modulated radiotherapy—A follow-up study. Radiother Oncol. 2009;90:408–412
  34. Zelefsky MJ, Ginor RX, Fuks Z, et al. Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45:567–570
  35. Lehrer S, Stone NN, Droller MJ, et al. Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer. Urol Oncol. 2002;7:73–76
  36. Saitoh M, Ramirez E, Babaian RJ. Ultrasonic volume monitoring in patient with prostate cancer treated by external beam radiation therapy. Urology. 1994;43:342–348

 Note—An online CME test for this article can be taken at http://astro.org/MOC.

 Conflict of interest: none.

PII: S0360-3016(10)00525-0

doi: 10.1016/j.ijrobp.2010.03.040

International Journal of Radiation Oncology * Biology * Physics
Volume 80, Issue 4 , Pages 1080-1086 , 15 July 2011

Article Tools

* Image Usage & Resolution